Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Issue 3 (3rd April 2018)

• Record Type: Journal Article
• Authors: Yeo, Crystal Jing Jing; Simmons, Zachary
• Is Part Of: Amyotrophic lateral sclerosis and frontotemporal degeneration. Volume 19:Issue 3/4(2018)
• Page Start: 167
• Page End: 172
• Publication Date: 2018-04-03
• Subjects: Amyotrophic lateral sclerosis -- edaravone -- ethics -- quality of life; 616.839
• DOI: 10.1080/21678421.2018.1425455
• Languages: English
• ISSNs: 2167-8421

Abstract

Abstract: The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare providers with a fiduciary responsibility to our patients, we must make sure they are fully informed about both the costs and benefits of non-curative therapies such as edaravone, and be prepared to discuss these in the context of their goals of care and potential impact on quality of life. Respect for our patients' autonomy is critical when discussing these issues, but we should always be guided by the ethical principles of beneficence and non-maleficence.